Phathom Pharmaceuticals, Inc.
PHAT
$3.31
$0.165.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 1,391.58% | 4,249.56% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,391.58% | 4,249.56% | -- | -- | -- |
| Cost of Revenue | 774.18% | 2,184.43% | -- | -- | -- |
| Gross Profit | 1,568.57% | 4,919.22% | -- | -- | -- |
| SG&A Expenses | 52.35% | 34.54% | 225.27% | 300.65% | 233.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.42% | 26.25% | 144.39% | 166.94% | 138.94% |
| Operating Income | -12.74% | 14.97% | -98.54% | -143.84% | -132.58% |
| Income Before Tax | -13.84% | 6.43% | -97.90% | -123.23% | -119.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -13.84% | 6.43% | -97.90% | -123.23% | -119.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.84% | 6.43% | -97.90% | -123.23% | -119.10% |
| EBIT | -12.74% | 14.97% | -98.54% | -143.84% | -132.58% |
| EBITDA | -12.83% | 15.02% | -98.67% | -144.17% | -133.00% |
| EPS Basic | 7.67% | 24.55% | -73.87% | -84.89% | -58.98% |
| Normalized Basic EPS | 7.67% | 24.54% | -73.87% | -84.88% | -58.98% |
| EPS Diluted | 7.67% | 24.55% | -73.87% | -84.89% | -58.98% |
| Normalized Diluted EPS | 7.67% | 24.54% | -73.87% | -84.88% | -58.98% |
| Average Basic Shares Outstanding | 23.30% | 24.00% | 13.82% | 20.74% | 37.82% |
| Average Diluted Shares Outstanding | 23.30% | 24.00% | 13.82% | 20.74% | 37.82% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |